Larimar Therapeutics holds steady after earnings miss amid Breakthrough Therapy optimism
Clinical-stage biotech posts $62.5M Q4 loss but investors focus on regulatory pathway for Friedreich's ataxia treatment
Larimar Therapeutics shares remained largely unchanged on Thursday after the clinical-stage biotech reported a wider-than-expected fourth-quarter loss, as investors looked past disappointing financial results to focus on regulatory progress for its lead drug candidate.
The Pennsylvania-based company reported a net loss of $62.5 million for the final quarter of 2025, more than double the $28.8 million loss recorded in the same period a year earlier. Despite the significant earnings shortfall, the stock closed the session barely moved, reflecting investor enthusiasm for [nomlabofusp], a treatment for Friedreich's ataxia that recently received FDA Breakthrough Therapy Designation.
The February regulatory milestone proved transformative for Larimar, sending shares up more than 32 percent when announced. The designation was granted based on clinical data showing increases in skin frataxin levels alongside consistent improvements across four key clinical outcomes: modified Friedreich's Ataxia Rating Scale (mFARS) score, FARS-Activities of Daily Living, 9-Hole Peg Test, and Modified Fatigue Impact Scale.
"The FDA has indicated willingness to consider skin FXN as a novel surrogate endpoint for BLA submission and is aligned with the plan to have a global confirmatory Phase 3 study underway at the time of BLA submission," the company stated, outlining a regulatory pathway that could lead to accelerated approval.
Larimar has mapped out a clear development timeline, with topline open-label study data expected in the second quarter of 2026, supporting a Biologics License Application submission planned for June 2026. The global confirmatory Phase 3 study is scheduled to initiate patient screening in the second quarter, with first patient dosing by mid-2026. If regulatory approval proceeds on schedule, a U.S. launch could occur in the first half of 2027.
The clinical progress comes at a cost. For the full year 2025, research and development expenses climbed to $154.2 million, reflecting preparations for nomlabofusp's commercialization scale-up. The company reported a pro forma cash position of $244.5 million as of December 31, 2025, following a successful $107.6 million public offering in February 2026. This cash runway extends into the second quarter of 2027, providing the company adequate funding to reach key regulatory and commercial milestones.
Wall Street remains broadly optimistic about Larimar's prospects. Analysts maintain a consensus "Strong Buy" rating on the stock, with an average 12-month price target of approximately $16.60, representing more than three-fold upside from current levels around $4.30. Among covering analysts, 11 recommend either "Buy" or "Strong Buy," with no hold or sell ratings, according to recent market data.
Friedreich's ataxia is a rare, degenerative neuro-muscular disorder that affects approximately 1 in 50,000 people in the United States. There are currently no FDA-approved treatments for the disease, which typically begins in childhood or adolescence and progressively impairs movement and coordination. The rarity of the condition and the absence of approved therapies contributed to the FDA's willingness to consider accelerated approval pathways based on surrogate endpoints.
Larimar's trajectory exemplifies a growing trend in biotechnology investing, where clinical-stage companies with promising rare disease treatments can command premium valuations despite mounting losses, provided they demonstrate clear regulatory pathways and commercial viability. The company's ability to secure Breakthrough Therapy Designation—typically reserved for drugs that show substantial improvement over available therapies—has significantly de-risked its development program and strengthened its competitive position in the rare disease space.
Investors will be closely watching several catalysts in the coming months, including the expected release of open-label study data in the second quarter, initiation of the Phase 3 confirmatory study, and progress toward the June BLA submission. These milestones will test whether analyst enthusiasm translates into regulatory success and ultimately into a viable commercial treatment for patients with Friedreich's ataxia.